Findings from two studies show high rates of complete remissions in patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer 

Practice changing results of event-free survival and overall survival are reported from the NIAGARA study

The first results from two phase III studies of Ra-223 and ¹⁷⁷Lu-PNT2002 may help to decipher their role in the treatment of patients with mCRPC 

Final overall survival data from the CONTACT-02 study are negative, but a survival advantage was observed with the novel combination in patients with liver or bone metastasis

First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group 

Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery

In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests

Survival benefits of the radioligand therapy needs to be confirmed in further studies

Cabozantinib plus atezolizumab may represent a novel option for patients progressing on first-line hormonal therapy 

In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers